Eikon Therapeutics opened higher at $6.78, compared with its previous close of $6.67. In the last trading session, the stock traded between $5.84 and $6.82. It showed a downward intraday trend.
An investment of $100 made 1 year ago in Eikon Therapeutics is now worth
$ 40.36
Resulting in a loss of
$ 59.64 (59.64%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.62 (-9.24%)
Day High
$6.82
Day Low
$5.84
Day Open
$6.78
Prev Close
$6.67
Volume
6,93,740
1W Return
-5.42%
1M Return
-16.49%
3M Return
-40.97%
6M Return
-39.16%
1Y Return
-59.64%
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
1.27
PEG Ratio
-
ROE
-
ROCE
-64.67%
EPS (TTM)
-
1 Week
-5.42%
1 Month
-16.49%
3 Months
-40.97%
6 Months
-39.16%
9 Months
-58.22%
Eikon Therapeutics Q3FY26 Results: EPS loss of $1.59 beats estimate
Eikon Therapeutics reported a Q3FY26 loss per share of $(1.59), beating the analyst consensus estimate of $(1.68) by 5.36%. Net loss attributable to common stockholders widened to $86.1 million from $71.1 million in the prior-year period. R&D expenses increased 21% YoY to $71.8 million due to increased clinical trial activity and compensation costs. The company holds $461.7 million in cash and equivalents, extending its operational runway into Q1 2028. Loss per share increased 93.44% YoY from $(24.24) in the same period last year.
TodayHC Wainwright initiates Eikon Therapeutics with Buy rating, $23 target
HC Wainwright & Co. initiated coverage on Eikon Therapeutics with a Buy rating. The assigned price target for the stock is $23. Analyst Sara Nik authored the coverage initiation.
27 days agoEikon Therapeutics files IND for EIK1006 to treat prostate cancer
Eikon Therapeutics filed an IND application with the FDA for EIK1006. EIK1006 targets advanced metastatic prostate cancer. The drug is a novel androgen receptor antagonist. It is structurally unrelated to current lutamide-class antagonists.
28 days agoEikon Therapeutics to present at Cantor and Morgan Stanley conferences
Eikon Therapeutics executives to speak at two September 2026 investor conferences. CEO Roger Perlmutter and CFO Freddie Bowie will lead fireside chats in New York. First appearance at Cantor Global Healthcare Conference on September 10, 2026. Second appearance at Morgan Stanley Global Healthcare Conference on September 15, 2026. Live webcasts available via company investor relations website for 30 days post-event.
2mo agoEikon Therapeutics CEO to speak at KOL event on PARP inhibitors
Eikon Therapeutics CEO Roger Perlmutter will speak at a KOL event on August 20, 2026, hosted by Cantor Fitzgerald. The event features Dr. Timothy Yap from UT MD Anderson Cancer Center discussing PARP inhibitors in oncology. The webcast will be archived on Eikon's investor relations site.
2mo agoEikon Therapeutics to join Russell 3000 Index effective June 26
Eikon Therapeutics, Inc. will be added to the Russell 3000 Index effective June 26, 2026, following the annual reconstitution. The inclusion reflects the company's standing among the largest US equities by market cap. The Russell 3000 Index measures the performance of approximately 3,000 stocks, representing 98% of the investable US equity market.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 1 year ago in Eikon Therapeutics is now worth
$ 40.36
Resulting in a loss of
$ 59.64 (59.64%)
Note: Past profits do not guarantee future returns.
